PHILADELPHIA (PRWEB) July 15, 2019
China Focus @ Bio Philadelphia, hosted by MyBioGate and CUBIO Innovation Center, sponsored by Hangzhou Investment Promotion Bureau, Fox Rothschild LLP, MORE Health and Henlius, was held at Loews Philadelphia Hotel on June 2, 2019.
The conference attracted Fosun Pharmaceuticals, WuXi Biologics, Kelun Pharmaceutical, Harbin Pharmaceuticals, Fountain Medical, Luye Life Science, Johnson&Johnson, Novartis, GlaxoSmithKline, Janssen, numerous Chinese and foreign drug companies, Silicon Valley Bank, Cedrus Group, Rui Jian Capital, Northern Light, Share Capital and other investment institutions, as well as PricewaterhouseCoopers, Frost&Sullivan and other well-known consulting firm.
The whole China Focus Forum was divided into four parts, composed of the main forum on "Cross-border Collaboration in Biotech and Pharma" and "AI and Digital Health", Pitch and Match, MyBioGate Global Healthcare Innovation Competition, and the exhibition.
During the forum, panelists delivered in-depth conversation in regards to opportunities and challenges with cross-border investment and partnership, impact of AI on pharmaceutical industry, as well as emerging Chinese biotech & pharma industry.
Ms. Xinxin Li, Vice President of Strategic Cooperation of MyBioGate, addressed in her opening speech at the China Focus Forum, “China’s biomedical industry has been developing rapidly in recent years.
More and more Chinese pharmaceutical companies are going abroad. Though in recent months, trade frictions between China and the United States have brought some uncertainties to the collaboration of both countries, China's health care market demand and size made it irresistible. That is also the idea of holding the China Focus Forum - linking China and overseas healthcare innovation.”
“Global biopharma investment will become more rational in 2019. At the same time, series A financing and, merger and acquisition of innovative diagnostic and technology platform enterprises will continue to increase”, Ms. Katherine Andersen, Senior Marketing Manager and Head of U.S. Life Sciences & Healthcare Relationship Banking at Silicon Valley Bank addressed in her keynote speech.
Senior manager of PricewaterhouseCoopers Health Research Institute, Alexander Gaffney delivered "Impact of FDA's new digital health approach on life sciences and healthcare", which focused on the changes digital technology bring to the health industry and the development prospects of this industry, from a regulatory policy and market perspective.
Organizers of China Focus Forum also invited the innovative projects to participate at the 1-on-1 meetings, roadshows, as well as Q&A sessions, generated fruitful results, based on attendees. Enterprises from China and the United States carried out comprehensive exhibitions of their enterprise from products, brand concept and core competitiveness.
When asked about the role that the platform serve on this cross-border collaboration, Ms. Xinxin Li said with confidence, “China Focus Forum has become an authoritative platform by MyBioGate and CUBIO, to provide cross-border services for overseas medical and healthcare startups to meet with Chinese pharmaceutical companies and investment institutions.”
China Focus is bringing together investors, pharma leaders and innovators from China and around the world for an exclusive partnering event designed to inspire, educate and foster cross-border investment and collaboration in leading biopharma innovations. The forum features premier 1-to-1 networking opportunities prior to and during the forum.
More information regards China Focus Forum maybe found at https://events.mybiogate.com/.
If you would like more information about this topic, please call (832)-497-2220, or email info(at)mybiogate.com
Feier Chen, MyBioGate